Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [ 177 Lu]Lu-DOTATATE: results from the LuDO-N trial.

Eur J Nucl Med Mol ImagingJun 19, 2026 (epub)
Clinical ResearchOncology (Medical)PediatricsRadiology (Diagnostic)Open access

Se Whee Sammy Park, Fredrik Sundquist, Leonor Teles et al.

✦ AI-curated · Sources linked

In 30 seconds

The LuDO-N trial evaluated the safety and dosimetry of a two-fraction regimen of [177Lu]Lu-DOTATATE in 14 patients with high-risk neuroblastoma. The study found that the tumour-to-kidney and tumour-to-whole-body absorbed dose ratios decreased significantly by 44% after the second fraction, indicating effective dose management while maintaining safety limits.

Key findings

  • Tumour-to-kidney and tumour-to-whole-body absorbed dose ratios decreased by 44% after the second fraction.
  • Tumours received a median 53% lower absorbed dose per administered activity in the second fraction.
  • Kidney and whole-body doses per activity were reduced by 24% and 18%, respectively.
  • No sustained renal toxicity was observed in the patient cohort.

Why it matters

This study highlights the importance of optimizing dosimetry in molecular radiotherapy for neuroblastoma, potentially improving treatment efficacy while minimizing risks to critical organs. Understanding these dynamics can guide clinicians in tailoring therapies for high-risk patients.

Source

PubMed · PMID 42315639Free full text on PubMed Central

Published in Eur J Nucl Med Mol Imaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.